News · 26 weeks24+100%
2026-04-192026-10-11
Mix1190d
- Other5(45%)
- SEC Filings4(36%)
- Analyst1(9%)
- Insider1(9%)
Latest news
25 items- PRMediciNova CEO Provides Shareholder UpdateLA JOLLA, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the "Company"), today provides shareholders an update on key findings from the recent topline results of its Phase 2 clinical trial evaluating MN-001 for the treatment of nonalcoholic fatty liver disease and hypertriglyceridemia associated with type 2 diabetes mellitus in the following letter from CEO Yuichi Iwaki, Ph.D. To Fellow Shareholders, We continue to advance our key programs to create viable treatments for both metabolic disease and amyotrophic lateral sclerosis
- PRMediciNova to Participate in the Maxim Growth SummitLA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the "Company"), announces that management will participate in the Maxim Growth Summit taking place October 12-14, 2026, at the Hard Rock Hotel New York. Management will be available for one-on-one meetings with investors registered for the event. Investors interested in scheduling a meeting with MediciNova management should contact their Maxim representative or visit here for more information. About MediciNova MediciNova, Inc. is a clinical-stage biopharmaceutical compan
- INSIDERFormerly 10% Owner 3d Investment Partners Pte. Ltd. sold $1,728,000 worth of shares (640,000 units at $2.70) (SEC Form 4)4 - MEDICINOVA INC (0001226616) (Issuer)
- SECSEC Form 8-K filed by Medicinova Inc8-K - MEDICINOVA INC (0001226616) (Filer)
- PRMediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)LA JOLLA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the topline results from MN-001-NATG-202, a Phase 2 clinical trial evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM). In the MN-001 group, reductions in serum triglycerides (TG), increases in serum high-density lipoprotein cholesterol (HDL-C) and HDL particle concentration (HDL-P), and a numerical trend toward improvement in liver fat and body
- PRMediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of the last patient, last visit (LPLV) in the double-blind portion of COMBAT-ALS, a Phase 2b/3 clinical trial evaluating MN-166 (ibudilast) for the treatment of Amyotrophic Lateral Sclerosis (ALS). A total of 234 participants were randomized to two treatment arms at clinical sites in the United States and Canada. Participants who remain active in the study are continuing treatment with MN-166 in the Open-Label Extension phase. The LPLV for th
- ANALYSTRoth Capital initiated coverage on MediciNova with a new price targetRoth Capital initiated coverage of MediciNova with a rating of Buy and set a new price target of $6.00
- PRMediciNova to Participate in Two Investor Conferences in SeptemberLA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the "Company"), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer, will participate in two investor conferences during September. H.C. Wainwright 28th Annual Global Investment Conference, September 14-16 at the Lotte New York Palace Hotel. Management will hold one-on-one meetings with investors during the conference. A virtual presentation will be available on demand here starting Friday, September 11th at 7:00
- SECSEC Form 8-K filed by Medicinova Inc8-K - MEDICINOVA INC (0001226616) (Filer)
- SECSEC Form 8-K filed by Medicinova Inc8-K - MEDICINOVA INC (0001226616) (Filer)
- SECSEC Form 10-Q filed by Medicinova Inc10-Q - MEDICINOVA INC (0001226616) (Filer)
- PRMediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patientsLA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the target enrollment of 200 patients has been achieved in the SEANOBI-ALS study (Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers in ALS ; NCT 06743776) evaluating MN‑166 (ibudilast) in patients with amyotrophic lateral sclerosis (ALS). The Expanded Access Program SEANOBI study is funded by National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of Health (NIH) supported under the ACT for ALS. Th
- PRMediciNova CEO Provides Shareholder UpdateLA JOLLA, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today provides shareholders a corporate update in the following Letter to Stockholders from CEO Yuichi Iwaki, M.D., Ph.D. Dear Fellow Shareholders, MediciNova continues to make significant progress across its key programs, most recently anchored by the completion of the last patient last visit in our Phase 2 clinical trial of MN-001-NATG-202 evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated wit
- INSIDERSEC Form 4 filed by Director Nagao Hideki4 - MEDICINOVA INC (0001226616) (Issuer)
- INSIDERSEC Form 4 filed by Director Lemerond Nicole4 - MEDICINOVA INC (0001226616) (Issuer)
- INSIDERSEC Form 4 filed by Director Beaver Carolyn4 - MEDICINOVA INC (0001226616) (Issuer)
- SECMedicinova Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - MEDICINOVA INC (0001226616) (Filer)
- PRMediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma TreatmentLA JOLLA, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application that covers the use of ibudilast (MN-166) in combination with an immune checkpoint inhibitor, specifically an anti-PD-1 antibody, for the treatment of glioblastoma. This patent allowance is expected to further strengthen the intellectual property position supporting the Company's combination therapy development strategy. Kazuko Matsuda, MD,
- PRMediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)LA JOLLA, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of last patient last visit (LPLV) in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM). The MN-001-NATG-202 study is a multicenter, randomized, double-blind, placebo-controlled trial evaluating MN-001 (tipelukast). Patients were randomized 1:1 to receive either 500 mg/day of MN-001 (ti
- SECSEC Form 10-Q filed by Medicinova Inc10-Q - MEDICINOVA INC (0001226616) (Filer)
- SECSEC Form DEFA14A filed by Medicinova IncDEFA14A - MEDICINOVA INC (0001226616) (Filer)
- SECSEC Form DEF 14A filed by Medicinova IncDEF 14A - MEDICINOVA INC (0001226616) (Filer)
- PRNew Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical TranslationLA JOLLA, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that a study conducted by researchers at the Spanish National Cancer Research Centre (CNIO) has identified macrophage migration inhibitory factor (MIF)–mediated reprogramming of CD74‑positive microglia and macrophages as a central vulnerability in brain metastasis. The research, recently published in the peer‑reviewed journal "Cancer Research" (March 2026), demonstrates pharmacological modulation of this pathway using the brain‑penetrant small molecule ibud
- SECSEC Form PRER14A filed by Medicinova IncPRER14A - MEDICINOVA INC (0001226616) (Filer)
- SECSEC Form PRE 14A filed by Medicinova IncPRE 14A - MEDICINOVA INC (0001226616) (Filer)
MNOV FAQ
6 questionsWhat does Medicinova Inc do?
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221...Where does MNOV stock trade?
Medicinova Inc (MNOV) is listed on NASDAQ.What sector and industry is MNOV in?
Medicinova Inc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about MNOV?
Medicinova Inc has had 2 recent analyst actions on file. The most recent action was from Roth Capital: Buy with a $600.00 price target on 2026-09-17. Recent price targets range from $600.00 to $1000.00.What companies are similar to MNOV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare MNOV side-by-side with any of them on Quantisnow.How can I track MNOV on Quantisnow?
Quantisnow aggregates Medicinova Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MNOV to receive live email and push alerts on every new disclosure.